EMEA-000052-PIP01-07-M03

Key facts

Invented name
Caprelsa
Active substance
Vandetanib
Therapeutic area
Oncology
Decision number
P/0285/2013
PIP number
EMEA-000052-PIP01-07-M03
Pharmaceutical form(s)
Tablet
Condition(s) / indication(s)
Treatment of medullary thyroid carcinoma
Route(s) of administration
Oral use
Contact for public enquiries
AstraZeneca AB (Sweden)

E-mail: paediatrics@astrazeneca.com
Tel. +46 8 5532 7591

Decision type
PM: decision on the application for modification of an agreed PIP
Compliance procedure number
EMEA-C-000052-PIP01-07-M03
Compliance opinion date
20/06/2014
Compliance outcome
positive

Decision

How useful was this page?

Add your rating